4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Publishes 2023 Corporate Responsibility Report

Ionis to hold first quarter 2024 financial results webcast

Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Medtronic (MDT)

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Ionis to present at upcoming investor conferences

Ionis to hold olezarsen Phase 3 data webcast

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle

First Drug to Treat Common, Lethal Liver Disease Gets US Nod

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals